{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 46 of 128', '11. Cutaneously applied treatments in regions other than the hands, which could interfere', 'with clinical trial evaluations or pose a safety concern within 1 week prior to baseline.', '12. Treatment with any marketed biological therapy or investigational biologic agents', '(including immunoglobulin, anti-IgE, and dupilumab):', 'Any cell-depleting agents including but not limited to rituximab: within', '6 months prior to baseline, or until lymphocyte count returns to normal,', 'whichever is longer.', 'Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to', 'baseline.', '13. Treatment with any non-marketed drug substance (that is, an agent which has not yet', 'been made available for clinical use following registration) within the last 4 weeks', 'prior to baseline or 5 half-lives whichever is the longest.', '14. Clinically significant infection within 4 weeks prior to baseline which, in the opinion', 'of the investigator, may compromise the safety of the subject in the trial, interfere with', \"evaluation of the IMP, or reduce the subject's ability to participate in the trial.\", 'Clinically significant infections are defined as:', 'A systemic infection.', 'A serious skin infection requiring parenteral (intravenous or intramuscular)', 'antibiotics, antiviral, or antifungal medication.', '15. Tuberculosis requiring treatment within 12 months prior to screening and/or subjects with', 'a positive blood test for tuberculosis at screening*.', '* Subjects with high risk of latent tuberculosis (e.g. prior residence in or travel to', 'countries with high prevalence of tuberculosis, close contact with a person with active', 'tuberculosis, or a history of active or latent tuberculosis where an adequate course of', 'treatment cannot be confirmed) must be tested.', '16. History of any known primary immunodeficiency disorder including a positive human', 'immunodeficiency virus (HIV) test at screening, or the subject taking antiretroviral', \"medications as determined by medical history and/or subject's verbal report.\", '17. Major surgery within 8 weeks prior to screening, or planned in-patient surgery or', 'hospitalisation during the trial period.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 47 of 128', '18. History of cancer:', 'Subjects who have had basal cell carcinoma, localised squamous cell', 'carcinoma of the skin or in situ carcinoma of the cervix are eligible provided', 'that the subject is in remission and curative therapy was completed at least', '12 months prior to screening.', 'Subjects who have had other malignancies are eligible provided that the', 'subject is in remission and curative therapy was completed at least 5 years', 'prior to screening.', '19. Any disorder, including but not limited to cardiovascular, gastrointestinal, hepatic,', 'renal, neurological, musculoskeletal, infections, endocrine, metabolic, haematological,', 'immunological, psychiatric, or major physical impairment, which is not stable in the', 'opinion of the investigator and could:', 'Affect the safety of the subject throughout the trial.', 'Influence the findings of the trial or their interpretations.', \"Impede the subject's ability to complete the entire duration of the trial.\", '20. Any abnormal finding which may:', 'Put the subject at risk because of their participation in the trial.', 'Influence the results of the trial.', \"Influence the subject's ability to complete the trial.\", 'The abnormal finding must be clinically significant and observed during the screening', 'period. Examples include abnormal findings in physical examination, vital signs,', 'ECG, haematology, clinical chemistry, or urinalysis.', '21. Positive hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb),', 'hepatitis B core antibody (HBcAb), or hepatitis C virus antibody (anti-HCV) serology', 'at screening. Subjects with positive HBsAb may be randomised provided they are', 'hepatitis B vaccinated and have negative HBsAg and HBcAb.', '22. Alanine aminotransferase or aspartate aminotransferase level >2.0 times the upper', 'limit of normal range (ULN) at screening.', '23. Known or suspected hypersensitivity to any component(s) of the IMP.', '24. Current participation in any other interventional clinical trial.', '25. Previously randomised in this clinical trial.']\n\n###\n\n", "completion": "END"}